<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">METHSCOPOLAMINE BROMIDE</span><br/>(meth-skoe-pol'a-meen)<br/><span class="topboxtradename">Pamine<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">anticholinergic (parasympatholytic)</span>; <span class="classification">antimuscarinic</span>; <span class="classification">antispasmodic</span><br/><b>Prototype: </b>Atropine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2.5 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Quaternary ammonium derivative of scopolamine that lacks the CNS actions of scopolamine. Its spasmolytic and antisecretory
         actions are quantitatively similar to those of atropine but they last longer.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Greater selectivity in blocking vagal impulses from GI tract than either scopolamine or atropine.</p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct in treatment of peptic ulcer, irritable bowel syndrome, and a variety of other GI conditions. Also may be used to
         control excessive sweating and salivation, migraine headaches, and premenstrual cramps.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to any of the drug's constituents; prostatic hypertrophy; pyloric obstruction; intestinal atony; tachycardia,
         cardiac disease; pregnancy (category C), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Older adult and debilitated patients.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Irritable Bowel Syndrome</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2.55 mg 30 min a.c. and h.s.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give 30 min before meals and at bedtime.</li>
<li>Preserve in tight, light-resistant containers.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> GI:</span> Dry mouth, constipation. <span class="typehead">Special Senses:</span> Blurred vision. <span class="typehead"> CNS:</span> Dizziness, drowsiness, flushing of skin. <span class="typehead">Urogenital:</span> Urinary hesitancy or retention. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Amantadine,</b> <span class="classification">tricyclic antidepressants</span> increase anticholinergic effects; may increase effects of <b>atenolol,</b> <b>digoxin;</b> may decrease effectiveness of <span class="classification">phenothiazines</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Erratic after PO administration. <span class="typehead">Onset:</span> Approximately 1 h. <span class="typehead">Duration:</span> 46 h. <span class="typehead">Elimination:</span> Excreted primarily in urine and bile; some unchanged drug excreted in feces. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Incidence and severity of adverse effects are generally dose-related. Dosage is usually maintained at a level that produces
            slight dryness of mouth.
         </li>
<li>Report urinary retention promptly; may indicate discontinuation.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Make position changes slowly and in stages.</li>
<li>Learn measures to relieve dry mouth; rinse mouth frequently with water, suck hard candy.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>